Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease.

[1]  C. Mantzoros,et al.  The global burden of metabolic disease: Data from 2000 to 2019. , 2023, Cell metabolism.

[2]  B. Blomberg,et al.  Weight gain during treatment course of allogenic hematopoietic stem cell transplantation, in patients with hematological malignancies, affects treatment outcome. , 2022, Cytotherapy.

[3]  E. Lontchi-Yimagou,et al.  Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals. , 2022, Diabetes research and clinical practice.

[4]  T. Ikizler,et al.  Hematologic malignancies magnify the effect of body mass index on insulin resistance in cancer survivors , 2022, Blood advances.

[5]  N. Kröger,et al.  Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study , 2021, Bone Marrow Transplantation.

[6]  C. Cheung,et al.  Prevalence of Metabolic Syndrome in the United States National Health and Nutrition Examination Survey (NHANES) 2011-2018 , 2021, medRxiv.

[7]  J. Passweg,et al.  New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation , 2020, In Vivo.

[8]  Sin-Ho Jung,et al.  Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality , 2020, PloS one.

[9]  R. Wong,et al.  Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. , 2020, JAMA.

[10]  T. Gooley,et al.  Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  I. Kabbash,et al.  High Body Mass Index (BMI) Is Associated with Lower Survival and Increased Chronic GVHD after Allogeneic Hematopoietic Stem Cell Transplantation. , 2019, Biology of Blood and Marrow Transplantation.

[12]  L. Jara,et al.  Metabolic syndrome, autoimmunity and rheumatic diseases , 2018, Pharmacological research.

[13]  J. H. Kim,et al.  HbA1c Cutoff for Prediabetes and Diabetes Based on Oral Glucose Tolerance Test in Obese Children and Adolescents , 2018, Journal of Korean medical science.

[14]  T. Akinyemiju,et al.  Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988–2012 , 2017, Preventing chronic disease.

[15]  M. Valenti,et al.  Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study , 2017, PloS one.

[16]  C. Hennekens,et al.  Metabolic Syndrome , 2017, Journal of cardiovascular pharmacology and therapeutics.

[17]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[18]  W. Garvey,et al.  Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. , 2014, Metabolic syndrome and related disorders.

[19]  F. Reis,et al.  Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. , 2014, Biochemical pharmacology.

[20]  T. Takayama,et al.  Body fat percentage as a marker of new-onset diabetes mellitus after kidney transplantation. , 2013, Transplantation proceedings.

[21]  J. Shelhamer,et al.  National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  S. Steinberg,et al.  Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity , 2011, Leukemia.

[23]  H. Nakasone,et al.  Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients. , 2011, Blood.

[24]  L. Phillips,et al.  Screening for Diabetes and Pre-Diabetes With Proposed A1C-Based Diagnostic Criteria , 2010, Diabetes Care.

[25]  M. Baldini,et al.  Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation , 2008, Bone Marrow Transplantation.

[26]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  J. Armitage,et al.  Prognostic factors of chronic graft‐versus‐host disease after allogeneic blood stem‐cell transplantation , 2005, American journal of hematology.

[28]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[29]  P. Hari,et al.  Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  L. Martínez-Dolz,et al.  Incidence of development of obesity after heart transplantation according to the calcineurin inhibitor. , 2015, Transplantation proceedings.

[31]  S. Samson,et al.  The Metabolic Syndrome: A Common Hyperinsulinemic Disorder With Severe Health Effects , 2006 .

[32]  P. Liu,et al.  Metabolic syndrome in hematologic malignancies survivors: a meta-analysis , 2014, Medical Oncology.

[33]  E. White,et al.  Fibrotic and sclerotic manifestations of chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  K. Ness,et al.  High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation , 2009, Bone Marrow Transplantation.

[35]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.